Previous 10 | Next 10 |
ChemoCentryx, Inc. (CCXI) Q1 2019 Earnings Conference Call May 06, 2019, 17:00 ET Company Participants Bill Slattery - Burns McClellan Thomas Schall - Founder, President, CEO & Chairman Susan Kanaya - EVP, Chief Financial & Administrative Officer and Secretary Conferen...
ChemoCentryx, Inc. (NASDAQ: CCXI ): Q1 GAAP EPS of -$0.23 beats by $0.03 . More news on: ChemoCentryx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., May 06, 2019 (GLOBE NEWSWIRE) -...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
MOUNTAIN VIEW, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market close on Monday, May 6, 2019. ChemoCentryx executive management will host a conference call and...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
MOUNTAIN VIEW, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. BST. T...
MOUNTAIN VIEW, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), announced today that, effective March 27, 2019, Rita Jain, M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics, has been appointed to the Company's Board of Directors. Dr. J...
March 26, 2019 Palm Beach, FL – March 26, 2019 – Research for the cure for cancer has become this generation’s version of President John F. Kennedy’s May 25, 1961 proclamation to “… landing a man on the Moon and returning him safely”. ...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...